Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:52 UTC |
---|
HMDB ID | HMDB0015125 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Exemestane |
---|
Description | Exemestane, also known as aromasin, belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Exemestane is an extremely weak basic (essentially neutral) compound (based on its pKa). |
---|
Structure | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1 |
---|
Synonyms | Value | Source |
---|
6-Methyleneandrosta-1,4-diene-3,17-dione | ChEBI | Exemestano | ChEBI | Exemestanum | ChEBI | Aromasin | Kegg | Examestane | HMDB | Aromasine | HMDB | Aromasil | HMDB |
|
---|
Chemical Formula | C20H24O2 |
---|
Average Molecular Weight | 296.4034 |
---|
Monoisotopic Molecular Weight | 296.177630012 |
---|
IUPAC Name | (1S,2R,10R,11S,15S)-2,15-dimethyl-8-methylidenetetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-diene-5,14-dione |
---|
Traditional Name | exemestane |
---|
CAS Registry Number | 107868-30-4 |
---|
SMILES | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C |
---|
InChI Identifier | InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1 |
---|
InChI Key | BFYIZQONLCFLEV-DAELLWKTSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- Oxosteroid
- 17-oxosteroid
- 3-oxosteroid
- 3-oxo-delta-1,4-steroid
- Delta-1,4-steroid
- Cyclic ketone
- Ketone
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 155.13 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0068 g/L | Not Available | LogP | 3.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.7 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 18.9391 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.99 minutes | 32390414 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2689.3 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 576.3 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 227.4 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 277.8 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 481.6 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 674.8 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 805.4 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 84.3 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1652.6 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 504.9 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1594.7 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 523.3 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 462.3 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 338.3 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 576.8 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Exemestane,1TMS,isomer #1 | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(O[Si](C)(C)C)=CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 | 2747.1 | Semi standard non polar | 33892256 | Exemestane,1TMS,isomer #1 | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(O[Si](C)(C)C)=CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 | 2418.4 | Standard non polar | 33892256 | Exemestane,1TMS,isomer #1 | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(O[Si](C)(C)C)=CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 | 3022.5 | Standard polar | 33892256 | Exemestane,1TBDMS,isomer #1 | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(O[Si](C)(C)C(C)(C)C)=CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 | 2981.8 | Semi standard non polar | 33892256 | Exemestane,1TBDMS,isomer #1 | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(O[Si](C)(C)C(C)(C)C)=CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 | 2610.5 | Standard non polar | 33892256 | Exemestane,1TBDMS,isomer #1 | C=C1C[C@@H]2[C@H](CC[C@]3(C)C(O[Si](C)(C)C(C)(C)C)=CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12 | 3178.5 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Exemestane GC-MS (Non-derivatized) - 70eV, Positive | splash10-0gc0-0490000000-1b1c46e80815c179a447 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Exemestane GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-qTof , Positive-QTOF | splash10-0002-0790000000-46727c37da42caccba4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-QTOF , positive-QTOF | splash10-0002-0190000000-5e04b3359ea2370bbde1 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-QTOF , positive-QTOF | splash10-0002-0950000000-0daf2c711395130c78a2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-QTOF , positive-QTOF | splash10-006t-0910000000-58ddee06caa2cdb4eeac | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-QTOF , positive-QTOF | splash10-006t-0910000000-64dd2bfc1eef30f5b766 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-QTOF , positive-QTOF | splash10-00wa-0900000000-ec533e47176e668d1ee9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-ITFT , positive-QTOF | splash10-004i-0980000000-457e7fb9bd5073d9521a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-ITFT , positive-QTOF | splash10-0002-0090000000-cc584f39a06f24401467 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-ITFT , positive-QTOF | splash10-0002-1960000000-22b6bd7c2ccea9c0c648 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-ITFT , positive-QTOF | splash10-00dj-2910000000-32edf95f8027c36c74ce | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Exemestane LC-ESI-ITFT , positive-QTOF | splash10-05fu-3900000000-84dacb108ccc2572ab41 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Exemestane 10V, Positive-QTOF | splash10-0002-0090000000-f8aaffa2c09a551a7d69 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Exemestane 20V, Positive-QTOF | splash10-002b-0290000000-dc2ea5e87de49e0a95f8 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Exemestane 40V, Positive-QTOF | splash10-0udi-2490000000-6bcc7507771cadb1be82 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Exemestane 10V, Negative-QTOF | splash10-0002-0090000000-cc26a78111c90014bbc4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Exemestane 20V, Negative-QTOF | splash10-0002-0090000000-6c59d18db75b7bfa2b7f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Exemestane 40V, Negative-QTOF | splash10-00ou-2090000000-0dafb14d21bf327e27c5 | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00990 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00990 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00990 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 54278 |
---|
KEGG Compound ID | C08162 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Exemestane |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 60198 |
---|
PDB ID | EXM |
---|
ChEBI ID | 4953 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Robinson A: A review of the use of exemestane in early breast cancer. Ther Clin Risk Manag. 2009 Feb;5(1):91-8. Epub 2009 Mar 26. [PubMed:19436613 ]
- Untch M, Jackisch C: Exemestane in early breast cancer: a review. Ther Clin Risk Manag. 2008 Dec;4(6):1295-304. [PubMed:19337436 ]
- Abrial C, Durando X, Mouret-Reynier MA, Thivat E, Bayet-Robert M, Nayl B, Dubray P, Pomel C, Chollet P, Penault-Llorca F: Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. Int J Gen Med. 2009 Jul 30;2:129-40. [PubMed:20360896 ]
- Nabholtz JM: Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag. 2008 Feb;4(1):189-204. [PubMed:18728707 ]
- Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70. [PubMed:17307102 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
---|